+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 108 Actively Recruiting clinical trials

R

Actively Recruiting

Researchers are evaluating the effectiveness and safety of elenestinib BLU-263 combined with symptom directed therapy SDT compared to placebo plus SDT in adults with indolent systemic mastocytosis ISM whose symptoms are not well controlled by SDT alone. This Phase 23 randomized, double-blind, placebo-controlled study includes participants from Parts 1 and 2 with ISM, with those in Part 2 continuing into Part 3 for open-label elenestinib treatment. Part K enrolls participants with prior use of selective KIT inhibitors, and additional pharmacokinetic groups will also participate. Participants receive SDT tailored individually and take either oral elenestinib or matching placebo once daily. In Part 1, treatment continues until study completion, while Part 2 involves approximately 48 weeks of dosing. Part 3 and other parts may extend treatment up to about 5 years. The study monitors participants throughout these periods, with dosing and symptom management adjusted as needed. During the study, participants undergo various assessments including symptom scoring with the Indolent Systemic Mastocytosis-Symptom Assessment Form ISM-SAF, safety monitoring for adverse events, and laboratory tests such as serum tryptase levels and KIT D816V allele fraction. Bone marrow mast cells, bone mineral density, and quality of life measures are also evaluated. Researchers track these outcomes at multiple timepoints from baseline up to 5 years to understand treatment impact and participant safety.

Age: 18Years +All GendersPhase 2Phase 3
88 locations
P

Actively Recruiting

Researchers are studying MK-7262, a trial medicine designed to lower Lipoproteina Lpa levels in the blood. The study aims to learn about the effects of MK-7262 alone and in combination with another trial medicine called enlicitide, which belongs to a group of medicines that lower low-density lipoprotein cholesterol LDL-C. This Phase 2 clinical trial evaluates the ability of these medicines to reduce Lpa and LDL-C levels and assesses their safety and tolerability. Participants will be randomly assigned to one of four groups MK-7262 with enlicitide, MK-7262 alone, enlicitide alone, or placebo for both medicines. All treatments are given orally once daily for up to approximately 12 weeks. The study is double-blind with placebo controls, and the medicines are taken as coated tablets. The trial monitors effects at specific time points including weeks 8 and 12. During the trial, participants will undergo blood tests to measure changes in Lpa and LDL-C levels from baseline. Researchers will track adverse events and monitor safety for up to about 20 weeks. The primary outcomes include percent changes in Lpa and LDL-C at week 8 and the number of participants experiencing side effects or discontinuing treatment due to side effects. Participation lasts for the treatment period and follow-up assessments.

Age: 18Years +All GendersPhase 2
76 locations
G

Actively Recruiting

Researchers are studying the impact and burden of three skin conditions moderate or severe alopecia areata, non-segmental vitiligo, and moderate to severe hidradenitis suppurativa. The study includes adolescents and adults and aims to understand how these conditions affect quality of life and daily functioning in a large global population. This is an observational study where participants with each condition will have a single visit for data collection following routine clinical practice. No experimental treatments are given instead, the study gathers information during this one visit to assess disease characteristics and impact. During the visit, participants will complete questionnaires and clinical assessments specific to their condition. These include tools measuring symptom impact, hair loss severity, skin depigmentation, and quality of life related to each disease. This helps researchers better understand the real-world burden of these conditions. Participation involves only this one visit, with no long-term follow-up or additional procedures.

Age: 12Years +All Genders
116 locations
R

Actively Recruiting

Researchers are investigating the use of tagraxofusp in adult patients with Blastic Plasmacytoid Dendritic Cell Neoplasm BPDCN, focusing on how well the treatment works and its safety in typical clinical settings. This observational registry study aims to gather real-world data on patients who are either new to tagraxofusp treatment or have relapsedrefractory disease after prior therapies. The study is sponsored by Stemline Therapeutics, Inc. and seeks to understand treatment outcomes in everyday medical practice. Participants in this study are adults diagnosed with BPDCN who are prescribed tagraxofusp monotherapy, either as first-line treatment or after relapse. The study does not provide the medication instead, it observes patients receiving tagraxofusp through their usual care. Two groups are included those newly starting tagraxofusp and those who have relapsed or are refractory to other treatments. The study tracks these patients over time to evaluate treatment responses and safety. Participants will be monitored for up to several years, with key assessments including the number of participants achieving complete response after about 3 months of treatment and the occurrence of capillary leak syndrome up to approximately 51 months. Additional outcomes include stem cell transplant rates, progression-free survival, overall survival, response duration, adverse events, and treatment dosing details up to 66 months. The study involves regular data collection from medical records and clinical follow-ups to assess these outcomes and track patient safety throughout the observation period.

Age: 18Years +All Genders
41 locations
S

Actively Recruiting

Researchers are evaluating ziltivekimab, a new medicine not yet approved anywhere, to see if it can reduce plaque buildup in the hearts blood vessels in people who have had a heart attack. The study focuses on patients with acute myocardial infarction and compares the effects of ziltivekimab against a placebo. This phase 3 trial aims to understand the impact of ziltivekimab on heart vessel plaque over about 15 months. Participants will be randomly assigned to receive either ziltivekimab or a placebo, both given as monthly injections under the skin for 12 months alongside standard heart care. The study uses advanced imaging techniques like intravascular ultrasound, near-infrared spectroscopy, and optical coherence tomography to monitor changes in the arteries. The treatment is administered shortly after participants undergo certain heart procedures. During the study, participants will undergo detailed heart imaging and blood tests at the start, at 4 weeks, and at 52 weeks to measure changes in plaque volume and inflammation markers. Researchers will monitor heart-related events like heart attacks, strokes, and deaths throughout the year. The study includes adherence tracking and safety monitoring to evaluate the treatments effects and any risks over the full duration.

Age: 18Years +All GendersPhase 3
20 locations
E

Actively Recruiting

This research aims to compare two surgical approaches for patients experiencing increased intracranial pressure caused by malignant stroke. It investigates whether using a single surgery with an individually molded space-expanding shield can be a viable alternative to the standard decompressive hemicraniectomy followed by a second surgery called cranioplasty. The study is planned as a randomized, controlled, multicenter trial to evaluate these methods in stroke patients aged 18 to under 70. Participants will be randomly assigned to one of two groups. The experimental group will receive decompressive hemicraniectomy with implantation of a space-expanding shield that allows brain swelling while providing protection in a single surgery. The control group will undergo the standard decompressive hemicraniectomy without the shield and later undergo cranioplasty about 90 days after the initial surgery. Follow-up examinations are scheduled at 1 to 7 days, 6 weeks, 3 months, and 6 months after surgery. During the study, participants will undergo evaluations including neurological assessments and imaging to monitor recovery and complications. Researchers will measure outcomes such as the modified Rankin Scale score at 6 months, number of additional surgeries for intracranial pressure control, infections, wound healing, syndrome of the trephined, survival, cosmetic satisfaction, and quality of life. The total duration of participation for each patient is 6 months, with safety and recovery closely monitored throughout.

Age: 18Years - 70YearsAll GendersPhase Not Applicable
6 locations
E

Actively Recruiting

Researchers are studying the effectiveness and safety of combining inavolisib with a cyclin-dependent kinase 4 and 6 inhibitor CDK46i and letrozole compared to placebo with CDK46i and letrozole. This study focuses on adults with endocrine-sensitive PIK3CA-mutated hormone receptor-positive, HER2-negative advanced breast cancer. The trial is a phase III, randomized, double-blind, placebo-controlled study aiming to improve first-line treatment options for this condition. Participants will be randomly assigned to receive either oral inavolisib once daily alongside letrozole and a CDK46 inhibitor or a matching placebo with letrozole and CDK46 inhibitor. The CDK46 inhibitor is given on either days 1-21 or days 1-28 of each 28-day treatment cycle. Both groups will follow this treatment regimen throughout the study period. During the trial, participants will be monitored regularly to assess progression-free survival, overall survival, and various measures of treatment response and quality of life, including pain and physical function. Safety will be closely tracked by recording adverse events and treatment-related symptoms using patient-reported outcomes. The study may last up to seven years, including long-term follow-up to evaluate the effects of the treatments over time.

Age: 18Years +All GendersPhase 3
242 locations
P

Actively Recruiting

Researchers are evaluating neladalkib NVL-655, an oral drug, in a Phase 12 study for patients with advanced ALK-positive non-small cell lung cancer NSCLC and other solid tumors. The study aims to assess the safety and tolerability of neladalkib, determine the recommended phase 2 dose, and evaluate its antitumor activity. A sub-study also investigates potential interactions between neladalkib and other drugs such as midazolam, repaglinide, and itraconazole in patients with advanced ALK-positive NSCLC. The study includes Phase 1 dose escalation to find the safe dose and Phase 2 dose expansion with six patient groups based on prior treatments and tumor types. Patients receive daily oral neladalkib. The sub-study enrolls patients into two cohorts to study drug interactions involving midazolam, repaglinide, and itraconazole. Eligible patients may have received various prior therapies including ALK tyrosine kinase inhibitors TKIs, chemotherapy, or immunotherapy depending on their cohort. Participants will undergo regular assessments such as scans and lab tests to monitor disease response and safety. Researchers will measure outcomes including dose limiting toxicities, objective response rate, duration of response, progression-free survival, overall survival, and quality of life over approximately three years. The study also monitors drug levels and adverse events closely, including in the drug interaction sub-study, with follow-up extending to months after the last dose.

Age: 12Years +All GendersPhase 1Phase 2
74 locations
C

Actively Recruiting

Researchers are evaluating whether antibiotic treatment is necessary for children with community-acquired pneumonia caused by the bacterium Mycoplasma pneumoniae. This trial compares the effects of a commonly used antibiotic, azithromycin, with a placebo in children aged 3 to 17 years. The study addresses concerns about increasing antibiotic resistance and aims to improve treatment decisions for this common cause of pneumonia in children. Participants are randomly assigned to receive either azithromycin or a placebo for five days. The azithromycin group takes a daily dose of 10mgkg on the first day followed by 5mgkg on days 2 through 5. This randomized, double-blind, placebo-controlled trial takes place across multiple pediatric centers and includes both ambulatory and hospitalized children. The study involves initial screening to confirm Mycoplasma pneumoniae infection using a specific antibody test before starting the assigned treatment. During the study, researchers will monitor symptom duration, vital signs, and changes in patient care status for up to 28 days. They will also assess overall clinical outcomes, symptom resolution, quality of life impacts on the family, time to return to normal daily activities, and the development of any complications related to the infection. Follow-up includes clinical examinations and parent reports to track progress and safety throughout the study period.

Age: 3Years - 17YearsAll GendersPhase Not Applicable
13 locations
S

Actively Recruiting

Healthy Volunteer

This research aims to evaluate a new advanced wireless skin sensor system designed to monitor vital signs in healthy newborn infants of at least 35 weeks gestational age. The study focuses on assessing the feasibility, safety, and accuracy of this wireless system compared to the standard wired monitoring during the first two hours after birth, especially during unsupervised parental care in the obstetrical center. The goal is to improve early detection and prevention of Sudden Unexpected Postnatal Collapse SUPC, a rare but serious condition affecting newborns shortly after delivery. Participants will have both the wireless monitoring system and the standard wired system placed on their chest and limb. For vaginal births, the wireless system is placed first, followed by the wired system after 15-20 minutes for C-section births, the order of placement is randomized. Both monitoring systems remain in place for two hours to continuously record vital signs such as heart rate, respiratory rate, oxygen saturation, and skin temperature. During the study, newborns vital signs will be recorded and compared between the two systems for up to two hours immediately after delivery. Researchers will evaluate the feasibility by checking for gaps in data and user satisfaction, assess safety through skin and pain scores, and measure accuracy using statistical comparisons. The study also includes monitoring the time between sensor placement and data display. Participation lasts only the initial two-hour period after birth, with monitoring done under real-world conditions in the obstetrical center.

Age: 35Weeks - 42WeeksAll GendersPhase Not Applicable
5 locations

1-10 of 108

1